Drug Trial Radar · NCT05062980
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Mar 30, 2022
Primary completion
Feb 3, 2025
Study completion Feb 3, 2025
Sponsor
- Lead sponsor
- Genprex, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa), in combination with pembrolizumab in patients with previously treated NSCLC. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene, and is a systemic gene therapy. The study will be conducted in 2 phases, a dose escalation phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2). In Phase 1, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with pembrolizumab to determine the recommended Phase 2 dose (RP2D). Phase 2 will be comprised of a dose expansion portion and a randomized portion. In the dose expansion portion, patients will be enrolled and treated with quaratusugene ozeplasmid at the RP2D in combination with pembrolizumab. In the randomized portion, patients will be randomized to receive either the investigational treatment of quaratusugene ozeplasmid at the RP2D in combination with pembrolizumab or a control treatment of either docetaxel +/- ramucirumab or the investigator's treatment of choice. Due to slow enrollment, the Accliam-2 trial was closed in Phase 1 and Phase 2 was not conducted.
Conditions
- Non Small Cell Lung Cancer
Interventions
quaratusugene ozeplasmidBiological
Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
pembrolizumabDrug
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
docetaxelDrug
Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
ramucirumabDrug
Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
Investigator's Treatment of ChoiceDrug
Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D) - Phase 1Time frame: First 21-days at each dose level
- Progression-free Survival (PFS) - Phase 2 Dose ExpansionTime frame: 18 weeks
- Progression-free Survival (PFS) - Phase 2 RandomizedTime frame: Approximately 8 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center - Magnolia Campus
Tampa, Florida
Ochsner Clinic Foundation
New Orleans, Louisiana
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey
Mary Crowley Cancer Research
Dallas, Texas
Millennium Oncology
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.